For the study, researchers from the Minneapolis Veterans Affairs Healthcare System monitored 240 veterans with chronic back pain or osteoarthritis for one year. Participants were either prescribed opioids or nonopioid pain medications to treat their pain.
Over the study period, pain interference with activities improved among both patient cohorts. The nonopioid group also reported higher reductions in pain intensity, according to the report. Overall, researchers noted the number of adverse symptoms reports did not vary between the groups, but the opioid cohort experienced a wider array of adverse effects.
“Opioids are perceived as strong pain relievers, but our data showed no benefits of opioid therapy over nonopioid medication therapy for pain,” said Erin Krebs, MD, a researcher with the Minneapolis VA Health Care System and the study’s lead author, according to an emailed release. “We already knew that opioids carry more risks of serious harms for patients. These new findings support the CDC recommendation that nonopioid therapies are preferred over opioids for long-term pain treatment.”
More articles on opioids:
Gov. Cuomo signs law investing $200M+ to fight New York opioid epidemic
Opioid epidemic increasing foster family demand in Vermont
Cherokee Nation files suit against drug wholesalers, pharmacies for role in opioid epidemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
